A Review on Probable Causes of Cardiotoxicity Caused by Common Cancer Drugs and the Role of Traditional Chinese Medicine in Prevention and Treatment
Miao Zhou,Wenyan Wang,Jiahao Weng,Zhikun Lai
DOI: https://doi.org/10.2147/pgpm.s427585
2023-12-06
Pharmacogenomics and Personalized Medicine
Abstract:Miao Zhou, 1, &ast Wenyan Wang, 2, &ast Jiahao Weng, 1 Zhikun Lai 1 1 Department of Cardiology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China; 2 Department of Endocrinology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jiahao Weng, Department of Cardiology, Shanghai municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, No. 274 Zhijiang Middle Road, Jingan District, Shanghai, 200071, People's Republic of China, Tel +86 13916958289, Email Cancer is a widespread disease in our nation, characterized by a high occurrence rate. The use of tumor medications has been linked to an increased chance of cardiovascular complications, including a notable occurrence of heart toxicity. This has caused significant concern among healthcare professionals. This article provides a comprehensive compilation of drugs recognized for their potential to cause heart toxicity. Furthermore, extensive research has been conducted to investigate and categorize the effects of heart toxicity, with the purpose of promoting awareness, facilitating early intervention, and ultimately reducing the occurrence of heart toxicity. At the same time, there is an anticipation that Traditional Chinese Medicine (TCM) can capitalize on its unique attributes to address such ailments. To establish its effectiveness, it is crucial to carry out extensive clinical trials or retrospective analyses. The purpose of this article is to summarize the possible mechanisms of cardiac toxicity caused by commonly used chemotherapy drugs and summarize the possible mechanisms of adverse cardiac toxicity, laying the groundwork for subsequent research. Keywords: chemotherapeutic drugs, cardiotoxicity, mechanisms, TCM intervention The increase in chronic illnesses, particularly cancer, has become a major concern for the well-being of the Chinese population due to factors such as the aging population, mounting living pressures, unhealthy lifestyles, and various other contributors. This worrying trend has been identified as a significant threat to the health of the Chinese people. According to the Global Burden of Disease 2019 (GBD2019) report, cancer was responsible for the death of 2.72 million individuals in China in 2019, accounting for nearly a quarter of all deaths that occurred in the country that year. 1 Contemporary scientific research has made significant progress in the timely detection, management, and overall survival rates of neoplastic diseases. However, individuals diagnosed with tumors or precancerous conditions now face an increased risk of experiencing cardiovascular health issues after undergoing cancer treatment. 2 In the past, this risk was not as apparent due to the shorter life expectancy of patients, which limited the time available for cardiovascular complications to arise and become a major concern. With the growing longevity of cancer patients, there is now a heightened concern regarding the cardiovascular complications associated with cancer treatments. Studies have revealed that subclinical cardiotoxicity caused by chemotherapy drugs affects up to 18% of patients, while clinical cardiotoxicity occurs in as many as 6% of cases. 3 The emergence of cardiotoxicity as a side effect of chemotherapy drugs poses a new challenge in terms of clinical diagnosis and treatment. 3 The purpose of this article is to summarize the possible mechanisms of cardiac toxicity caused by commonly used chemotherapy drugs and summarize the possible mechanisms of adverse cardiac toxicity, laying the groundwork for subsequent research. Bevacizumab (BVZ) is a type of antibody that is created using human genes and is designed to specifically target and block the function of vascular endothelial growth factor (VEGF). This action prevents the formation of new blood vessels (angiogenesis), which hampers the growth of cancerous cells and stops the spread of tumors. 4,5 As a result, it serves as an effective treatment option for various types of tumors such as colorectal cancer, lung cancer, breast cancer, cervical cancer, and more. The extensive utilization of Bevacizumab in clinical anti-tumor therapy highlights its significant value in achieving the goal of combating cancer. Various clinical trials have reported that the prevalence of BVZ-related hypertension ranges from 16% to 47%. 6,7 Moreover, the frequency of hypertension was found to be influenced by the dosage of BVZ given. 8 -Abstract Truncated-
pharmacology & pharmacy